US SB1662 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on May 23 2019 - 25% progression, died in committee
Action: 2019-05-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 23 2019 - 25% progression, died in committee
Action: 2019-05-23 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.
Title
Opioid Treatment Surge Act
Sponsors
| Sen. Jeff Merkley [D-OR] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-05-23 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB3105 (Same As) 2019-06-06 - Referred to the Subcommittee on Health.
Subjects
Drug, alcohol, tobacco use
Health
Health care coverage and access
Prescription drugs
User charges and fees
Health
Health care coverage and access
Prescription drugs
User charges and fees
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/senate-bill/1662/all-info |
| Text | https://www.congress.gov/116/bills/s1662/BILLS-116s1662is.pdf |
